Skip to main content
      Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rh

      Bella Mehta bella_mehta

      1 week 1 day ago
      Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases. Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7
      Predictors of retinopathy progression after HCQ discontinued?

      In the chart review of 28 pt records who had retinopathy,

      sheila RHEUMarampa

      1 week 1 day ago
      Predictors of retinopathy progression after HCQ discontinued? In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c Age - significant assoc'n with progression ✳️monitor toxicity more closely esp in older pts #ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
      A new IA drug in OA 🚨

      Cell therapy of apoptotic PBMCs ENX-CL-05-001
      RCT Ph2A moderate to severe OA
      134 pts 3 injecti

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      A new IA drug in OA 🚨 Cell therapy of apoptotic PBMCs ENX-CL-05-001 RCT Ph2A moderate to severe OA 134 pts 3 injections vs. PBO Pain improvement 24% Better response in people > 60 and more so 65yo Potential improvement for > 6mo Safety mainly local reactions to compound https://t.co/m2MZN3i22b
      Lung Ultrasound in CTD-ILD

      Prospective cohort 146 pts CTD-ILD
      30 preclinical ILD
      76 limited ILD
      40 extensive ILD

      Medi

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      Lung Ultrasound in CTD-ILD Prospective cohort 146 pts CTD-ILD 30 preclinical ILD 76 limited ILD 40 extensive ILD Median LUS scores higher if Extensive ILD LUS scores correlation w/ fibrosis severity, DLCO & FCV Agreement between LUS and HRCT severity 0.74 Excellent inter https://t.co/R9zGmCTT8Q
      Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO

      Mos. 4-6: >10% improvement in alopecia w/

      sheila RHEUMarampa

      1 week 1 day ago
      Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr
      52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA

      Primary ACR 50 16wks
      Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA Primary ACR 50 16wks Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW ACR50 50% 57% 51% ACR70 36% 42% 42% PASI100 55% 64% 58% MDA 47% 52% 47% No specific enthesitis data presented No new safety signal Next https://t.co/J18rSTmyze
      #ACR25 Abstr#2601 At single cell level using CyTOF, metabolic activity varied btw HC & autoimmune groups but cluster

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 1 day ago
      #ACR25 Abstr#2601 At single cell level using CyTOF, metabolic activity varied btw HC & autoimmune groups but clusters in At-Risk ANA+ve appeared closer to #SLE. ANA+ve who progressed to AI-CTD showed Plasmablast expansion & enhanced glycolysis. Could be used as target @RheumNow https://t.co/jtrM1wvQLk
      What's new in sjogren's?

      Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)

      Pt in both dosing

      Brian Jaros, MD Dr_Brian_MD

      1 week 1 day ago
      What's new in sjogren's? Promising phase III data of telitacicept (dual BLyS + APRIL neutralization) Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose Similar rates of adverse events @RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH
      Gut microbiome on Urate metabolism study- 1500 men and women.
      From 3 cohorts- Framingham, nurses health and men's lifes

      Bella Mehta bella_mehta

      1 week 1 day ago
      Gut microbiome on Urate metabolism study- 1500 men and women. From 3 cohorts- Framingham, nurses health and men's lifestyle with blood and stool data Focused on 5 urate metbolizing genes Abst#2590 #ACR25 @RheumNow https://t.co/YxBb3WfcbB
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      1 week 1 day ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
      Safety of CAR-T
      ×